You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Merck
since
auto-detected in 45 stories
9 days ago
Merck said on Thursday the U.S. FDA has approved its cholesterol pill, Lipfendra, the first of its kind to receive the health regulator's nod.
25 days ago
Stocks making the biggest moves premarket: AeroVironment, Strategy, Merck & more ○
These are the stocks posting the largest moves premarket.
30 days ago
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal ⊕
Merck KGaA has agreed to acquire biotech firm Bio-Techne for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.
64 days ago
Stocks making the biggest moves premarket: IMAX, Merck, Estee Lauder & more ○
These are the stocks posting the largest moves premarket.
86 days ago
Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook ⊕
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
3 months ago
Merck shares are forming a bullish chart pattern, and a breakout could be on the horizon ⊕
The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.
4 months ago
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline ⊖⊖
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck nears $6bn biotech deal to boost cancer drug pipeline ⊖
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Merck to create separate cancer business to offset Keytruda patent loss ⊖⊖
Merck said on Monday it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines.
5 months ago
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms ⊕
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.